Qalsody — Competitive Intelligence Brief

Qalsody (TOFERSEN) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antisense Oligonucleotide [EPC]. Area: Rare Disease.

marketed Antisense Oligonucleotide [EPC] Superoxide dismutase 1 (SOD1) mRNA Rare Disease Oligonucleotide

Target snapshot

Qalsody (TOFERSEN) — Biogen Ma. Qalsody works by binding to the messenger RNA (mRNA) of the Superoxide dismutase 1 (SOD1) gene, preventing its expression and reducing the production of the toxic SOD1 protein associated with ALS.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Qalsody TARGET	TOFERSEN	Biogen Ma	marketed	Antisense Oligonucleotide [EPC]	Superoxide dismutase 1 (SOD1) mRNA	2023-01-01
Amondys 45	CASIMERSEN	Sarepta	marketed	Antisense Oligonucleotide [EPC]	exon 53 of dystrophin pre-mRNA	2021-01-01
Vyondys 53	GOLODIRSEN	Sarepta	marketed	Antisense Oligonucleotide [EPC]	exon 53 of dystrophin pre-mRNA	2019-01-01
Exondys 51	ETEPLIRSEN	Sarepta	marketed	Antisense Oligonucleotide [EPC]	exon 51 of dystrophin pre-mRNA	2016-01-01
Kynamro	MIPOMERSEN	Kastle Theraps Llc	marketed	Antisense Oligonucleotide		2013-01-01
PF-07852352 Influenza saRNA 1	pf-07852352-influenza-sarna-1	Pfizer	marketed	antisense oligonucleotide	influenza virus
ISIS 3521	ISIS 3521	European Organisation for Research and Treatment of Cancer - EORTC	phase 3	Antisense oligonucleotide	Protein kinase C-alpha (PKC-alpha) mRNA

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antisense Oligonucleotide [EPC] class)

1. Sarepta · 3 drugs in this class
2. Biogen Ma · 1 drug in this class